´ëÇÑÁø´Ü°Ë»çÀÇÇÐȸ (¿Â¶óÀÎ&¿ÀÇÁ¶óÀÎ º´Çà) LMCE 2020 & KSLM 61st Annual Meeting : 2020-09-24±³À°ÀÏÀÚ : 2020-09-24
±³À°Àå¼Ò : ¿Â¶óÀÎ & ¿ÀÇÁ¶óÀÎ µ¿½Ã °³ÃÖ ¿¬¼ö±³À° (¿ÀÇÁ¶óÀÎ: ¼ÛµµÄÁº¥½Ã¾Æ Room A~F )
±³À°ÁÖÁ¦ :
(¿Â¶óÀÎ&¿ÀÇÁ¶óÀÎ º´Çà) LMCE 2020 & KSLM 61st Annual Meeting ÁÖÃÖ±â°ü : ´ëÇÑÁø´Ü°Ë»çÀÇÇÐȸ
´ã´çÀÚ : ±èÈñ¼ø
¿¬¶ôó : 02-795-9914
À̸ÞÀÏ :
kscp3@kams.or.kr ±³À°Á¾·ù : Áø´Ü°Ë»çÀÇÇаú
Âü¼®¿¹»óÀοø : 500¸í
Èñ¸ÁÆòÁ¡ : 6Á¡ (ÀÏ¹Ý 4Á¡ / Çʼö 2Á¡)
Áö¿ª :
ÀÎõ±¤¿ª½Ã±³À°½Ã°£ : 16 ½Ã°£ 0ºÐ
¼¼ºÎ¼ö°·á : 100,000¿ø
ºñ°í Á¤È¸¿ø-10¸¸¿ø/ÁØȸ¿ø.º´¸®»ç-8¸¸¿ø/ºñȸ¿ø-25¸¸¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 09¿ù 24ÀÏ Room C (Room 116-117) / ¿Â¶óÀÎ 08:00~08:20 SY5C: Current status of korean association of external quality assessment service and proficiency testing Kyunghoon Lee(Seoul National University College of Medicine Korea)
±³À°½Ã°£ 09¿ù 24ÀÏ Room C (Room 116-117) / ¿Â¶óÀÎ 08:20~08:40 SY5C: Result of 12 years implementing EQA for medical laboratories in Vietnam Truong Quan Thuy(Center for Standardization and Quality control in Medical Lab of Ho Chi Minh City Vietnam)
±³À°½Ã°£ 09¿ù 24ÀÏ Room C (Room 116-117) / ¿Â¶óÀÎ 08:40~09:00 SY5C: External quality assurance system in medical laboratories: Myanmar experience Wah Wah Aung(Advanced Molecular Research Centre Myanmar)
±³À°½Ã°£ 09¿ù 24ÀÏ Room C (Room 116-117) / ¿Â¶óÀÎ 09:00~09:20 SY5C: External quality assurance system in mongolia OYUNDELGER Munkhtuvshin Ertsuud(Mongolian Association of the Laboratory Medicine Mongolia)
±³À°½Ã°£ 09¿ù 24ÀÏ Room C (Room 116-117) / ¿Â¶óÀÎ 09:40~10:00 SY5C: Risk assessment for external quality assurance program --> Risk assessment for external quality assurance choices in clinical laboratories Yi-Ching Lin(College of Medicine Kaohsiung Medical University Taiwan)
±³À°½Ã°£ 09¿ù 24ÀÏ Room C (Room 116-117) / ¿Â¶óÀÎ 10:00~10:20 SY5C: External quality assurance system in clinical chemistry: Present status in India Praveen Sharma(All India Institute of Medical Sciences India)
±³À°½Ã°£ 09¿ù 24ÀÏ Room C (Room 116-117) / ¿Â¶óÀÎ 10:20~10:40 SY5C: Current status of external quality assurance system in japan Katsuo Kubono(Niigata University of Health and Welfare Japan)
±³À°½Ã°£ 09¿ù 24ÀÏ Room C (Room 116-117) / ¿Â¶óÀÎ 10:40~11:00 SY5C: Implementation of national external quality assurance scheme (EQAS) to achieve harmonization of laboratory result: indonesia¡¯s experience Agus Susanto Kosasih(Dharmais Hospital National Cancer Center Indonesia)
±³À°½Ã°£ 09¿ù 24ÀÏ Room A (Premier A+B) 08:30~09:00 SY6A: Vitamin B12 and folate deficiency and its laboratory investigation; Comparison of diagnostic accuracy of active B12 and total vitamin B12. Barnali Das(Kokilaben Dhirubhai Ambani Hospital & Medical Research Institute India)
±³À°½Ã°£ 09¿ù 24ÀÏ Room A (Premier A+B) 09:00~09:30 SY6A: Laboratory assessment in the diagnosis and management of parathyroid disease Soo Young Moon(Pusan National University School of Medicine Korea)
±³À°½Ã°£ 09¿ù 24ÀÏ Room A (Premier A+B) 09:30~10:00 SY6A: Urine free cortisol in the diagnosis of cushing¡¯s syndrome Jooyoung Cho(Yonsei University Wonju College of Medicine Korea)
±³À°½Ã°£ 09¿ù 24ÀÏ Room B (Premier C) 08:30~09:00 SY6B: PHEIC (Public Health Emergency of International Concern) Jeong Su Park(Seoul National University College of Medicine Korea)
±³À°½Ã°£ 09¿ù 24ÀÏ Room B (Premier C) 09:00~09:30 SY6B: SARS-CoV-2 & COVID-19 in Korea Heungsup Sung(University of Ulsan College of Medicine Korea)
±³À°½Ã°£ 09¿ù 24ÀÏ Room B (Premier C) 09:30~10:00 SY6B: EUA (Emergency Use Authorization) in Korea¡¯s Coronavirus outbreak Hyukmin Lee(Yonsei University College of Medicine Korea)
±³À°½Ã°£ 09¿ù 24ÀÏ Room A (Premier A+B)/ ¿Â¶óÀÎ 11:00~12:00 PL02: Clinical lab 2.0: How the laboratory can support value based care, optimize patient outcomes, and reduce total costs of care David G. Grenache(American Association for Clinical ChemistryTriCore Reference Laboratories USA)
±³À°½Ã°£ 09¿ù 24ÀÏ Room A (Premier A+B) 13:00~13:40 KS01: Genomics, Metabolomics and the diagnosis of rare diseases Ching-Wan Lam(The University of Hong Kong Hong Kong)
±³À°½Ã°£ 09¿ù 24ÀÏ Room A (Premier A+B)/ ¿Â¶óÀÎ 13:40~14:10 SY7A: What to Do When You Don¡¯t Have Tissue: Cell-Free Tumor DNA Christina M. Lockwood(University of Washington USA)
±³À°½Ã°£ 09¿ù 24ÀÏ Room A (Premier A+B)/ ¿Â¶óÀÎ 14:10~14:40 SY7A: What to Do When DNA Fails: RNA-Based Next-Generation Sequencing Seung-Tae Lee(Yonsei University College of Medicine Korea)
±³À°½Ã°£ 09¿ù 24ÀÏ Room A (Premier A+B)/ ¿Â¶óÀÎ 14:40~15:10 SY7A: What to Do When You Don¡¯t Have Enough: Droplet Digital PCR Vera Ashley Paulson(University of Washington USA)
±³À°½Ã°£ 09¿ù 24ÀÏ Room B (Premier C) 13:40~14:10 SY7B: Technical innovation and laboratory medicine and infection control Ki Ho Hong(Seoul Medical Center Korea)
±³À°½Ã°£ 09¿ù 24ÀÏ Room B (Premier C) 14:10~14:40 SY7B: New diagnostics test for HAI in primary-care hospitals Hyukmin Lee(Yonsei University College of Medicine Korea)
±³À°½Ã°£ 09¿ù 24ÀÏ Room B (Premier C) 14:40~15:10 SY7B: New approach to diagnosis of multidrug-resistant pathogens YoungJin Kim(Kyung Hee University School of Medicine Korea)
±³À°½Ã°£ 09¿ù 24ÀÏ Room B (Premier C) 15:10~15:40 SY7B: The current status of C. difficile infection diagnosis; meaning of laboratory diagnosis Bo-Mun Shin(Inje University College of Medicine Korea)
±³À°½Ã°£ 09¿ù 24ÀÏ Room C (Room 116-117) 13:40~14:00 SY7C: Major subjects of IVD regulations and designation for the institute of clinical performance test Seung Yong Lee(Ministry of Food and Drug Safety Korea)
±³À°½Ã°£ 09¿ù 24ÀÏ Room C (Room 116-117) 14:00~14:20 SY7C: Process of Emergency Use Authorization (EUA) in Korea and other countries Kyoung Ho Roh(National Health Insurance Service Ilsan Hospital Korea)
±³À°½Ã°£ 09¿ù 24ÀÏ Room C (Room 116-117) 14:20~14:40 SY7C: Experience of COVID-19 IVD approval for each country Jinkoo Kang(Seegene co. Korea)
±³À°½Ã°£ 09¿ù 24ÀÏ Room C (Room 116-117) 14:40~15:10 SY7C: Regulation and process of clinical performance test for IVD approval Young-Wook Ahn(National Institute of Food and Drug Safety Evaluation Korea)
±³À°½Ã°£ 09¿ù 24ÀÏ Room A (Premier A+B) / ¿Â¶óÀÎ 16:00~16:25 SY8A: Laboratory response for COVID019 in Korea: Lessons from the past Gab Jung Kim(°¨¿°º´Áø´Ü°ü¸®°ú Korea)
±³À°½Ã°£ 09¿ù 24ÀÏ Room A (Premier A+B) / ¿Â¶óÀÎ 16:25~16:50 SY8A: Laboratory response for COVID019 in Korea: For future 2nd wave Hyukmin Lee(Yonsei University College of Medicine Korea)
±³À°½Ã°£ 09¿ù 24ÀÏ Room A (Premier A+B) / ¿Â¶óÀÎ 16:50~17:10 SY8A: Genome-wide characterization of point mutations in SARS-CoV-2 Genome Jun-Sub Kim(¹ÙÀÌ·¯½ººÐ¼®°ú Korea)
±³À°½Ã°£ 09¿ù 24ÀÏ Room A (Premier A+B) / ¿Â¶óÀÎ 17:10~17:30 SY8A: Problem solving in SARS-CoV-2 molecular testing Heungsup Sung(University of Ulsan College of Medicine Korea)
±³À°½Ã°£ 09¿ù 24ÀÏ Room B (Premier C) 16:00~16:30 SY8B: Next-generation sequencing and next-generation flowcytometry in diagnostics of plasma cell disorder: Is it more useful and informative for treatment in real-world clinical settings? Hyun-Young Kim(Sungkyunkwan University School of Medicine Korea)
±³À°½Ã°£ 09¿ù 24ÀÏ Room B (Premier C) 16:30~17:00 SY8B: Diagnostics of myelodysplastic syndrome: Can the genetics open the door to perfect diagnosis? Young-Uk Cho(University of Ulsan College of Medicine Korea)
±³À°½Ã°£ 09¿ù 24ÀÏ Room B (Premier C) 17:00~17:30 SY8B: Germline variant screening in myeloid neoplasms: Should it be routinely tested in all patients? Borahm Kim(Korea University College of Medicine Korea)
±³À°½Ã°£ 09¿ù 24ÀÏ Room A (Premier A+B) / ¿Â¶óÀÎ 17:30~18:10 KS02: PML-RARA: Lessons from the chimera and the curable leukemia Scott C. Kogan(University of California USA)